Prostate Cell News

Prostate Cell News is an online resource summarizing the latest prostate cell research.

BjöRn Gysell Is Donating to Research into Future Treatments for Prostate Cancer

July 10, 2026

[Karolinska Institutet] A prostate cancer research initiative in Sweden has been made possible by a donation from Björn Gysell. The investment will enable Karolinska Institutet’s research environment in prostate cancer to develop the next generation diagnostics and therapies using AI, genomics and precision medicine.

SETDB1-Mediated Repression of RhoB Promotes EMT and Metastatic Progression in Prostate Cancer

July 10, 2026

[Oncogene] Scientists identified SET domain bifurcated 1 (SETDB1) as a key regulator of epithelial–mesenchymal transition (EMT) and metastasis through direct repression of RhoB, the small GTPase. SETDB1 is genomically amplified and transcriptionally upregulated in metastatic CRPC.

Functional and Omics-Based Rationale for the Induction of BRCAness by Androgen Receptor Pathway Inhibitors to Sensitize Prostate Cancer to PARP Inhibition, Regardless of HRR...

July 10, 2026

[British Journal of Cancer] Researchers assessed poly (ADP‒ribose) polymerase (PARP) inhibitors alone and with androgen receptor pathway inhibitors in prostate cancer cell lines, metastatic patient-derived organoids, and LN-metastatic tissue slice cultures.

NeoGenomics Launches FDA-Approved PTEN IHC Companion Diagnostic for Prostate Cancer

July 10, 2026

[NeoGenomics, Inc.] NeoGenomics, Inc. announced the launch of PTEN IHC CDx, the first immunohistochemistry (IHC) companion diagnostic test approved by the US FDA for patients with prostate adenocarcinoma.

Blue Earth Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial Investigating Actinium (²²⁵Ac) rhPSMA-10.1 Injection in Metastatic Castration-Resistant Prostate Cancer

July 10, 2026

[Blue Earth Therapeutics (BioSpace)] Blue Earth Therapeutics and University College London announced initiation of a Phase I clinical trial evaluating Actinium (225Ac) rhPSMA-10.1 Injection, an investigational alpha‑emitting PSMA‑targeted radiopharmaceutical for the treatment of patients within clinical trials in metastatic CRPC.

Lactate-Induced H3K4me3 Histone Mark Promotes PLOD1-Driven Prostate Cancer Invasion

July 10, 2026

[Cell Death & Disease] Investigators showed that the lactic acid-induced increase in succinate levels affects the activating H3K4me3 methylation mark in prostate cancer cells, promoting a pro-invasive phenotype.

A Ligandable PNT Domain Establishes ERG As a Directly Targetable Oncogenic Driver in Prostate Cancer

July 10, 2026

[Proceedings of the National Academy of Sciences of the United States of America] Researchers demonstrated continued dependency on ERG in metastatic prostate cancer and identified a druggable pocket within its N-terminal Pointed (PNT) domain.

Butyrylated PGAM5-Triggered and GSH-Responsive Cysteine Polymer Nanoparticles for CBL0137 Delivery to Enhance Necroptosis in Prostate Cancer

July 10, 2026

[Advanced Healthcare Materials] Scientists utilized a cysteine-based, GSH-responsive polymer to deliver a broad-spectrum antitumor agent CBL0137. Exploiting high GSH levels in prostate cancer cells, the resulting CBL0137-loaded nanoparticles achieved targeted and efficient intracellular delivery and enhanced tumor-killing efficacy.

Total Flavonoids from Ageratum conyzoides Synergize with Docetaxel to Induce Ferroptosis in Prostate Cancer Cells via the NRF2/SLC7A11/GPX4 Signaling Pathway

July 10, 2026

[Scientific Reports] The authors investigated whether the combined treatment of total flavonoids from Ageratum conyzoides and docetaxel (DTX) can enhance the antitumor effect of DTX on prostate cancer cells by regulating the NRF2/SLC7A11/GPX4 signaling axis and inducing mitochondria-related ferroptosis.

Neoadjuvant Intraprostatic Immunotherapy for High-Risk Localized Prostate Cancer

July 10, 2026

[Nature Reviews Urology] Novel immunotherapy approaches such as T cell-engager therapies, CD40 agonists and HSV-TK gene therapy have shown early promise for the treatment of prostate cancer.

Programmable mRNA 3′UTR Engineering Restores MHC-I and Overcomes Immune Evasion in Prostate Cancer

June 25, 2026

[Nature Biomedical Engineering] Scientists developed a programmable RNA engineering platform, termed the 3′UTR CRISPR/dCas13 Engineering System, to precisely manipulate mRNA alternative polyadenylation in vivo.

UCLA Researchers Awarded $1.7 Million Department of Defense Grant to Advance Next-Generation CAR T-Cell Therapies for Prostate Cancer

June 25, 2026

[UCLA Health] Researchers from the UCLA Health Jonsson Comprehensive Cancer Center have received a $1.7 million grant from the US Department of Defense’s Congressionally Directed Medical Research Programs to develop new strategies to improve CAR T-cell therapies for metastatic CRPC.

Published since 2010, Prostate Cell News compiles top scientific journal articles covering the characterization, behavior, and culturing of prostate cells. Additionally, our editorial team curates the latest press releases, technical advances, jobs, and events relevant to the prostate cell research community. Prostate Cell News saves scientists valuable time while keeping them informed in their field, facilitating the rapid exchange of cutting edge research updates and science news.